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Background: Heart involvement in patients with systemic sclerosis (SSc)
resembles the inflammatory dilated cardiomyopathy (iDCM) phenotype with
predominance of inflammation, fibrosis, vasculopathy and heart dysfunction.
Animal studies of iDCM indicated bone marrow originated cells as a major source
of pathological myofibroblasts. MicroRNAs are key regulators of immune cell
function and are involved in many cardiac pathological processes. However, their
roles in monocyte differentiation and fibrogenesis are unclear.
Objectives: To determine the role of circulating monocytes and microRNAs in
the onset and progression of myocardial fibrosis in SSc, we examined monocyte
differentiation and their microRNAs expression profile in SSc.
Methods: Endomyocardial biopsies from SSc/iDCM patients and healthy controls
were screened by immunohistochemistry. CD14+ monocytes isolated from
peripheral blood of SSc patients and healthy donors were differentiated towards
the myofibroblast phenotype by stimulation with TGF-β1, IL-4, IL-10 and IL-13. In
addition, CD14+ monocytes were co-cultured with dermal fibroblasts originated
from SSc patients and healthy subjects. After 7 days, myofibroblast gene
expression and cytokines secretion profile were evaluated. MicroRNA candidates
were selected using DIANA-TarBase v7.0 and TargetScan Release 7.0 and further
analysed by qPCR.
Results: Myocardium of SSc/iDCM patients (n=10) revealed extensive fibrosis
and accumulation of inflammatory cells including CD14+ monocytes. Moreover,
fibrotic myocardium from SSc patients exhibited the presence of CD14+/Fra-2+
monocyte-derived fibroblast-like cells. Bioinformatical analysis indicated several
potential microRNAs being involved in monocyte differentiation, and qPCR
confirmed predicted candidates. We observed decreased basal levels of let-7i
(Mann-Whitney U test, p=0.005), miR-10b (p=0.005), miR-21 (p=0.005), miR-29a
(p=0.005), miR-155 (p=0.002), miR-199a (p=0.008) and miR-544a (p=0.002),
and increased levels of miR-29b (p=0.03) in circulating CD14+ monocytes
isolated from SSc patients (n=10) compared to healthy controls (n=4). Stimulated
monocytes acquired a myofibroblast-like phenotype with increased expression
of collagen I, fibronectin, α smooth muscle actin and Fra-2 in comparison
to untreated cells. Similarly, CD14+ monocytes exposed to dermal fibroblasts
acquired myofibroblast features. CD14+ monocytes from SSc patients were
characterised by higher production of IP-10, MIP-3α, LIF and NT-3. The process
of monocyte to myofibroblast differentiation employed Fra-2/TGF-β signalling.
Inhibition of the canonical SMAD-dependent pathway with TGFβR1 inhibitors
resulted in the abrogation of monocyte-to-myofibroblast differentiation.
Conclusions: Here we demonstrated the capability of peripheral blood monocytes
to differentiate towards the myofibroblast phenotype, indicating these cells as one
of the potential sources of pathological tissue myofibroblasts in SSc. Different
miRNA expression profiles in SSc monocytes indicate a primary activation state.
Further studies of miRNAs regulation pathways might lead to novel treatment
strategies, particularly for heart involvement.
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